AbbVie Inc (AbbVie) is a diversified research-based biopharmaceutical company. Its primary activities include the discovery, development, manufacturing, and marketing of advanced therapies for complex and serious diseases. The company majorly focuses on the treatment of chronic rheumatological, gastroenterological, dermatological, neurological, viral, and metabolic diseases; cancer and other serious autoimmune diseases; and health conditions.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

AbbVie's R&D arm focuses on discovering and developing new pharmaceutical products. The company focuses on several therapeutic areas, including immunology, oncology, neuroscience, eye care, and aesthetics, complemented by additional focus areas such as virology. AbbVie Inc. employs advanced technologies like artificial intelligence, machine learning, and genomics to accelerate drug discovery and development. The company also emphasizes patient-focused drug development and precision medicine to deliver the right medicine for the right patient more efficiently. AbbVie Inc. supplements its R&D efforts through collaborations with third parties, acquisitions, and strategic venture capital investments in early-stage opportunities. AbbVie's R&D units are responsible for managing the company's research and development activities. These units are located across various sites globally, including Abbott Park, Illinois; Branchburg, New Jersey; Cambridge, Massachusetts; Irvine, California; Madison, New Jersey; Madison, Wisconsin; North Chicago, Illinois; Pleasanton, California; San Diego, California; South San Francisco, California; Waltham, Massachusetts; and Worcester, Massachusetts. Outside the United States, principal R&D facilities are located in Ludwigshafen, Germany, and Oxford, the UK. Some of its pipeline products include Lutikizumab to treat Hidradenitis Suppurativa; RINVOQ to treat Alopecia Areata, Hidradenitis Suppurativa, Systemic Lupus Erythematosus, and Takayasu Arteritis; Tavapadon to treat Parkinson's Disease; ELAHERE to treat Platinum-Sensitive Ovarian Cancer; Epkinly to treat First Line Follicular Lymphoma, and First Line Diffuse Large B-cell Lymphoma; Etentamig (ABBV-383) to treat Multiple Myeloma; Temab-A (ABBV-400) to treat Colorectal Cancer; VENCLEXTA to treat Acute Myeloid Leukemia post transplant; Surabgene Lomparvovec (ABBV-RGX-314) to treat wet AMD (subretinal); TrenibotE to treat Glabellar Lines and Armour Thyroid to treat Hypothyroidism. AbbVie has a broad global R&D footprint with over 14,000 scientists and staff working across 17 countries. The company has approximately 90 compounds, devices, or indications in development, either individually or under collaboration or license agreements. AbbVie has formed major technology alliances to enhance its R&D capabilities. In FY2025, the company spent US$9,096 million on R&D, which as a percentage of revenue, stood at 14.9%.